Filing Flows › Pacific Biosciences of California (PACB) › Q4 2025
Pacific Biosciences of California (PACB) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 25, 2026
Pacific Biosciences of California (PACB) reported revenue of $44.6M for the fourth quarter 2025 (Q4 2025), +14% from a year earlier and +16% from the quarter before. Operating margin was -92.3%, net loss $40.4M (90.4% of revenue).
Pacific Biosciences of California, Q4 2025: revenue $44.6M (+14% year over year), operating margin -92.3%, net loss $40.4M, operating cash flow −$19.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $44.6M | +16% | +14% |
| Operating profit | −$41.2M | — | — |
| Net earnings | −$40.4M | — | — |
| Operating cash flow | −$19.1M | — | — |
What changed
Revenue was $44.6M in Q4 2025, up 14% year over year and up 16% from the previous quarter. Consumables revenue was the largest line at 48% of revenue.
Gross margin was 37.1%, up 11.5 points from a year earlier. Operating costs exceeded revenue by $41.2M, an operating margin of -92.3%. Operating expenses fell 65% while revenue rose 14%. The quarter ended with a net loss of $40.4M, wider than the previous quarter's $38.0M loss.
Operating cash flow was −$19.1M. Non-cash charges added back $3.8M of depreciation and amortization and $9.6M of share-based compensation. Working capital and other items added $8.0M. Capital expenditures of $861K exceeded it, leaving free cash flow of −$19.9M.
Questions
What was Pacific Biosciences of California's revenue in the fourth quarter 2025?
Pacific Biosciences of California (PACB) reported revenue of $44.6M for the fourth quarter 2025 (Q4 2025), +14% from a year earlier and +16% from the quarter before.
Was Pacific Biosciences of California profitable in the fourth quarter 2025?
Operating loss was $41.2M (-92.3% of revenue) and net loss $40.4M.
Source: Pacific Biosciences of California 10-K on SEC EDGAR.